Bausch Health has acquired an exclusive license to develop and commercialize Novaliq’s dry eye disease treatment candidate NOV03 in the United States and Canada, according to a press release.
NOV03, a water-free, preservative-free solution that uses Novaliq’s EyeSol technology, addresses dry eye disease associated with meibomian gland dysfunction. A phase 2 study of the drug found improvement inf corneal fluorescein staining over control at 8 weeks and a statistically significant improvement in dry eye symptoms, the release said.
"Bausch Health remains focused on boosting our core
Uncategorized